Compare Dicks Sporting Goods Inc (DKS) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Inovio Pharmaceuticals Inc — how do they compare? Dicks Sporting Goods Inc trades at $203.63 (market cap $18.35B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Dicks Sporting Goods Inc is far larger — about 233.6× Inovio Pharmaceuticals Inc's market cap, and Dicks Sporting Goods Inc pays a 2.44% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| DKS | INO | |
|---|---|---|
Market Cap | $18.35B | $78.55M |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $2.87 |
52-Week Low | $187.78 | $0.66 |
Enterprise Value | $25.14B | $49.56M |
Dividend Yield | 2.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DKS trades at $203.44, down 4.98% on the day, amid a bearish technical signal. The company has consistently beaten earnings estimates in recent quarters, with strong profitability metrics including a 20.9% ROE and 4.71% net income margin. Analyst consensus is strongly bullish with a $263.22 price target and no sell ratings. Recent news highlights include positive coverage from Zacks and an upcoming Q2 2026 earnings call on August 25th.
The outlook remains positive given strong fundamentals and analyst support, but risks include competitive pressures and the stock's current bearish technical trend. The key near-term catalyst is the Q2 earnings report, which could validate the bullish sentiment if results meet or exceed the expected EPS of $3.77.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
